Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer

Gynecologic Oncology

Volumn 126, Issue 3, 2012, Pages 381-386

  Chang, Suk Joon ^a   Bristow, Robert E ^b   Ryu, Hee Sug ^a  

^a Ajou University School of Medicine   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Advanced ovarian cancer; Lymphadenectomy; Survival

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CYSTIC LYMPHANGIOMA; CYTOREDUCTIVE SURGERY; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; ILEUS; INTESTINE OBSTRUCTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVARIECTOMY; OVARY CANCER; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PARAAORTIC LYMPHADENECTOMY; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL TIME; WOUND DEHISCENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AORTA; CARBOPLATIN; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PACLITAXEL; PELVIS; PERITONEAL NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84864408250     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.05.014     Document Type: Article

References (21)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. K.K. Shih, and D.S. Chi Maximal cytoreductive effort in epithelial ovarian cancer surgery J Gynecol Oncol 21 2010 75 80
3. F. di Re, G. Baiocchi, R. Fontanelli, G. Grosso, L. Cobellis, and F. Raspagliesi Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases Gynecol Oncol 62 1996 360 365 (Pubitemid 26322426)
4. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 2002 1248 1259 (Pubitemid 34177431)
5. G.D. Aletti, S.C. Dowdy, B.S. Gostout, M.B. Jones, C.R. Stanhope, and T.O. Wilson Aggressive surgical effort and improved survival in advanced-stage ovarian cancer Obstet Gynecol 107 2006 77 85
6. D.S. Chi, E.L. Eisenhauer, J. Lang, J. Huh, L. Haddad, and N.R. Abu-Rustum What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103 2006 559 564 (Pubitemid 44602167)
7. M. Peiretti, V. Zanagnolo, G.D. Aletti, L. Bocciolone, N. Colombo, and F. Landoni Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Single institution experience Gynecol Oncol 119 2010 259 264
8. S. Kommoss, J. Rochon, P. Harter, F. Heitz, J.P. Grabowski, and N. Ewald-Riegler Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer Ann Surg Oncol 17 2010 279 286
9. E. Burghardt, F. Girardi, M. Lahousen, K. Tamussino, and H. Stettner Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer Gynecol Oncol 40 1991 103 106
10. J. Kigawa, Y. Minagawa, H. Itamochi, Y. Kanamori, H. Ishihara, and N. Terakawa Retroperitoneal lymphadenectomy, including the para-aortic nodes in patients with stage III ovarian cancer Am J Clin Oncol 17 1994 230 233 (Pubitemid 24160614)
11. C. Scarabelli, A. Gallo, A. Zarrelli, C. Visentin, and E. Campagnutta Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival Gynecol Oncol 56 1995 328 337
12. N.M. Spirtos, G.M. Gross, J.L. Freddo, and S.C. Ballon Cytoreductive surgery in advanced epithelial cancer of the ovary: the impact of aortic and pelvic lymphadenectomy Gynecol Oncol 56 1995 345 352
13. G.D. Aletti, S. Dowdy, K.C. Podratz, and W.A. Cliby Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer Am J Obstet Gynecol 195 2006 1862 1868 (Pubitemid 44792638)
14. R. Rouzier, C. Bergzoll, J.L. Brun, G. Dubernard, F. Selle, and S. Uzan The role of lymph node resection in ovarian cancer: analysis of the Surveillance, Epidemiology, and End Results (SEER) database BJOG 117 2010 1451 1458
15. H.S. Kim, W. Ju, B.C. Jee, Y.B. Kim, N.H. Park, and Y.S. Song Systematic lymphadenectomy for survival in epithelial ovarian cancer: a meta-analysis Int J Gynecol Cancer 20 2010 520 528
16. A. du Bois, A. Reuss, P. Harter, E. Pujade-Lauraine, I. Ray-Coquard, and J. Pfisterer Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials J Clin Oncol 28 2010 1733 1739
17. F. Parazzini, G. Valsecchi, G. Bolis, P. Guarnerio, S. Reina, and G. Polverino Pelvic and paraortic lymph nodal status in advanced ovarian cancer and survival Gynecol Oncol 74 1999 7 11 (Pubitemid 29331161)
18. A. Abe, H. Furumoto, M. Irahara, H. Ino, M. Kamada, and O. Naka The impact of systematic para-aortic and pelvic lymphadenectomy on survival in patients with optimally debulked ovarian cancer J Obstet Gynaecol Res 36 2010 1023 1030
19. P.B. Panici, A. Maggioni, N. Hacker, F. Landoni, S. Ackermann, and E. Campagnutta Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial J Natl Cancer Inst 97 2005 560 566 (Pubitemid 40723783)
20. S.J. Chang, and R.E. Bristow Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease Gynecol Oncol 125 2012 483 492
21. J.K. Chan, R. Urban, J.M. Hu, J.Y. Shin, A. Husain, and N.N. Teng The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13,918 patients Br J Cancer 96 2007 1817 1822 (Pubitemid 46912018)